Maternal Serum Screening for Down Syndrome, Trisomy 18, and Other Fetal Chromosome Abnormalities

Journal of Clinical Ligand Assay

Volumn 26, Issue 3, 2003, Pages 129-136

  Benn, Peter A ^a   Fang, Min ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Aneuploidy; Clinical chemistry; Down syndrome; Maternal serum screening; Prenatal diagnosis; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; INHIBIN A; PLASMA PROTEIN; PROTEIN A;

ANEUPLOIDY; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME XP; DOWN SYNDROME; FEMALE; FETUS; FETUS DISEASE; FETUS ECHOGRAPHY; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; KARYOTYPE 45,X; MATERNAL SERUM; MOSAICISM; PHENOTYPE; PREGNANCY COMPLICATION; PRENATAL SCREENING; REVIEW; SECOND TRIMESTER PREGNANCY; TRIPLOIDY; TRISOMY 16; TRISOMY 18;

EID: 1842477038     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Hook EB: Prevalence, risks and recurrence, in Brock DJH, Rodeck CH, Ferguson-Smith MA (eds): Prenatal Diagnosis and Screening. Edinburgh, Churchill Livingston. 1992, pp 351-392.
2. th edition. New York, McGraw-Hill. 1995. pp 749-794.
3. Egan JFX, Benn P, Borgida AF, et al.: Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997 Obstet Gynecol 2000;96:979-85.
4. Benn PA, Hsu LYF: Prenatal diagnosis of chromosomal abnormalities through amniocentesis, in Milunsky A (ed): Genetic Disorders and the Fetus. Fifth Edition. Baltimore: Johns Hopkins Press. 2004. In Press.
5. Palomaki GE, Knight GJ, McCarthy J, et al.: Maternal serum screening for Down syndrome in the United States: A 1995 survey. Am J Obstet Gynecol 1997;176:1046-1051.
6. Egan JFX, Kaminsky LM, DeRoche ME, et al.: Antenatal Down syndrome screening in the U. S. in 2001: A survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2002;187:1230-1234.
7. Cuckle HS, Wald NJ: Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387-402.
8. Hecht CA, Hook EB: The imprecision in rates of Down syndrome by 1-year maternal age intervals: a critical analysis of rates used in biochemical screening. Prenat Diagn 1994;14:729-738.
9. Hecht CA, Hook EB: Rates of Down syndrome at livebirth by one-year maternal age intervals in studies with apparent close to complete ascertainment in populations of European origin: a proposed rate schedule for use in genetic and prenatal screening. Am J Med Genet 1996;62:376-385.
10. Bray I, Wright DE, Davies C, Hook EB: Joint estimation of Down syndrome risk and ascertainment rates: a meta-analysis of nine published data sets. Prenat Diagn 1998;18:9-20.
11. Huether CA, Ivanovich J, Goodwin BS, et al.: Maternal age specific risk rate estimates for Down syndrome among live births in whites and other races from Ohio and metropolitan Atlanta. J Med Genet 1998;35:482-489.
12. Morris JK, Mutton DE, Alberman E: Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6.
13. Morris JK, Wald NJ, Mutton DE, Alberman E: Comparison of models of maternal age-specific live risk for Down syndrome live births. Prenat Diagn 2003;23:252-258.
14. Carothers AD, Hecht CA, Hook EB: International variation in reported livebirth prevalence rates of Down syndrome, adjusted for maternal age. J Med Genet 1999;36:386-393.
15. Carothers AD, Castilla EE, Dutra M da G, Hook EB: Search for ethnic, geographic, and other factors in the epidemiology of Down syndrome in South America: Analysis of data from the ECLAMC project, 1967-1997. Am J Med Genet 2001;103:149-156.
16. Hook EB, Topol BB, Cross PK: The natural history of cytogentically abnormal fetuses detected at midtrimester amniocentesis which are not terminated electively: new data and estimates of the excess and relative risk of later fetal death associated with 47, +21 and some other abnormal karyotypes. Am J Hum Genet 1989;45:855-861.
17. Hook EB, Mutton DE, Ide R, et al.: The natural history of Down syndrome conceptuses diagnosed parentally that are not electively terminated. Am J Hum Genet 1995;57:875-881.
18. Morris JK, Wald NJ, Watt HC: Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-145.
19. Cuckle H: Down syndrome fetal loss rate in early pregnancy. Prenat Diagn 1999;19:1177-1179.
20. Benn PA, Egan JFX: Survival of Down syndrome in utero. Prenat Diagn 2000;20:432-439.
21. Hook EB: Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol 1981;58:282-285.
22. Carothers AD, Collyer S, De Mey R, et al.: Parental age and birth order in the aetiology of some sex chromosome aneuploidies. Ann Hum Genet 1978;41:277-287
23. Hook EB, Warburton D: The distribution of chromosomal genotypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet 1983;64:24-27.
24. Carothers AD, Frackiewicz A, De Mey R, et al.: A collaborative study of the aetiology of Turner syndrome. Ann Hum Genet 1980;43:355-368.
25. Reynolds TM, Penny MD: The mathematical basis of multivariate risk screening: with special reference to screening for Down syndrome associated pregnancy. Ann Clin Biochem 1989;27:452-458.
26. Haddow JE, Palomaki GE: Prenatal screening for Down syndrome, in Simpson JL, Elias S (eds): Essentials of Prenatal Diagnosis. New York: Churchill Livingstone, 1993: pp185-220.
27. Larsen SO, Christiansen M, Norgaard-Pedersen B: Calculation of roc curves in multidimensional likelihood ratio based screening with Down's syndrome as a special case. J Med Screen 1998;5:57-62.
28. Wald NJ, Kennard A, Hackshaw A, McGuire A: Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246. www.ncchta.org/fullmono/mon201.pdf.
29. Benn PA: Advances in prenatal screening for Down syndrome: I general principles and second trimester testing. Clinica Chimica Acta 2002;323:1-16.
30. Cuckle H: Established markers in second trimester maternal serum. Early Hum Develop 1996;47:S27-S29.
31. Benn PA, Fang M, Egan JFX, et al.: Incorporation of Inhibin-A in second trimester screening for Down syndrome. Obstet Gynecol 2003;101:451-454.
32. Wald NJ, Huttley WJ, Hackshaw AK: Antenatal screening with the quadruple test. Lancet 2003;361:835-836.
33. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, et al.: Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998;18:1061-1067.
34. Benn PA: HCG and chromosome abnormalities. Downs Screening News 2003;10(1):22.
35. Palomaki GE, Haddow JE, Knight GJ, et al.: Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 1995;15:713-723.
36. Benn PA, Ying J, Beazoglou T, Egan JFX: Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. Prenat Diagn 2001;21:46-51.
37. Benn PA, Leo MV, Rodis JF, et al.: Maternal serum screening for trisomy 18: a comparison of fixed cut-off and patient-specific risk protocols. Obstet Gynecol 1999;93:707-711.
38. Hogge WA, Fraer L, Melegari T: Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol. Am J Obst Gynecol 2001;185:289-93.
39. Saller DN Jr, Canick JA, Blitzer MG, et al.: Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999;19:813-816.
40. Saller DN, Canick JA, Schwartz S, Blitzner MG: Multiple-marker screening in pregnancies with hydropic and non-hydropic Turner syndrome. Am J Obstet Gynecol 1992;67:1021-1024.
41. Benn PA, Ying J: Preliminary estimate for the second trimester maternal serum screening detection rate of 45,X using alphafetoprotein, unconjugated estriol, and human chorionic gonadotropin. J Matern Fetal Neonatal Med In press.
42. Benn PA, Gainey A, Ingardia CJ, et al.: Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn 2001;21:680-686.
43. Bradley LA, Canick JA, Palomaki GE, Haddow JE: Undetectable maternal serum unconjugated estriol levels in the second trimester: Risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 1997;176:531-535.
44. nd trimester screening for Down's syndrome. J Med Screen 2002;9:43-4
45. Benn P: Trisomy 16 and trisomy 16 mosaicism: a review. Am J Med Genet 1998;79:121-133.
46. Benn PA, Collins R: Abnormal maternal serum inhibin-A levels in trisomy 16 mosaic pregnancies. Am J Hum Genet 1999;65: A172.
47. Chen J-E, Hsu T-Y, Ou C-Y, et al.: Prenatal diagnosis of trisomy 20 mosaicism by maternal serum screening for Down syndrome. Eur J Obstet Gynecol 1999;86:175-177.
48. Wallerstein R, Yu M-T, Neu RL, et al.: Common trisomy mosaicism diagnosed in amniocytes involving chromosomes 13,18,20, and 21: karyotype-phenotype correlations. Prenat Diagn 2000;20:103-122.
49. Benn PA, Horne D, Briganti S, Greenstein RM: Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple marker testing as screen-positive for Down's syndrome. Am J Obstet Gynecol 1995;173:496-501
50. Benn PA: Advances in prenatal screening for Down syndrome: II first trimester testing and future directions. Clinica Chimica Acta 2002;24:1-11.
51. Krantz DA, Hallahan TW, Orlandi F, et al.: First trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96:207-213.
52. Schuchter K, Hafner E, Stangl G, et al.: The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 2002;22:211-215.
53. Spencer K, Spencer CE, Power M, et al.: Screening for chromosome abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective BJOG 2003;110:281-286.
54. Binda R, Heath V, Liao A, et al.: One-stop clinic for the assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219-225.
55. Snijders RJ, Noble P, Sebire N, et al.: UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;352:343-346.
56. Royal College of Obstetricians and Gynecologists. Recommendations arising from the study group on screening for Down syndrome in the first trimester. http:www.rcog.org.uk/study/downsyndrome.html.
57. Haddow JE: Antenatal screening for Down's syndrome: where are we and where next? Lancet 1998;352:336-337.
58. Cicero S, Curcio P, Papageorghiou A, et al.: Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001;358:1665-1667.
59. Tul N, Spencer K, Noble P, et al.: Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19:1035-1042.
60. Wald NJ, Hackshaw AK, Watt H: Nuchal translucency and trisomy 18. Prenat Diagn 2000;20:353-357.
61. Spencer K, Ong C, Skentou H, et al.: Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000;20:411-416.
62. Spencer K, Nicolaides KH: A First trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 2002;22:877-879.
63. Spencer K, Tul N, Nicolaides KH: Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 2000;20:390-394.
64. Spencer K, Liao AW, Skentou H, et al.: Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000;20:495-499.
65. Wald NJ, Watt HC, Hackshaw AK: Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-467.
66. Palomaki GE, Neveux LM, Knight GJ, Haddow JE: Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 2003;23:243-247.
67. Pajkrt E, Mol BWJ, Bleker OP, Bilardo CM: Pregnancy outcome and nuchal translucency measurements in fetuses with a normal karyotype. Prenat Diagn 1999;19:1104-1108.
68. Hyett JA, Sebire NJ, Snijders RJ, Nicolaides KH: Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol 1996;7:101-103.
69. Westergaard JG, Sinosich MJ, Bugge M, et al.: Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am J Obstet Gynecol 1983;145:67-69.
70. Al-Sebai MAH, Diver M, Hipkin LJ: The role of a single free β-human chorionic gonadotropin measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Hum Repod 1996;11:881-888.
71. Leporrier N, Herrou M, Morello R, Leymarie P: Fetuses with Down's syndrome detected by prenatal screening are more likely to abort spontaneously than fetuses with Down syndrome not detected by prenatal screening. BJOG 2003;110:18-21.
72. Benn PA, Egan JFX, Ingardia CJ: Extreme second trimester serum analytes in Down syndrome pregnancies with hydrops fetalis. J Matern Fetal Neonatal Med 2002;11:1-4.
73. Tanski S, Shulman Rosengren S, Benn PA: The predictive value of the triple screening test for the phenotype of Down syndrome. Am J Med Genet 1999;85:123-126.
74. Benn PA, Craffey A, Horne D, et al.: Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome. J Matern Fetal Med 2000;9:165-9.